Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53.
Brefeldin A (BFA) is a natural product that affects the structure and function of the Golgi apparatus and is in development for cancer chemotherapy. We observed that a wide range of cancer cells could undergo DNA fragmentation associated with apoptosis after BFA treatment. This DNA fragmentation was induced within 15 h in HL60 leukemia cells and after 48 h in K562 leukemia and HT-29 colon carcinoma cells with BFA concentrations as low as 0.1 microM. The DNA fragmentation had the typical internucleosomal pattern in HL60 and HT-29 cells. Apoptotic cells were also detected by microscopy. BFA-induced apoptosis is p53-independent as HL60 and K562 cells are p53 null and HT-29 are p53 mutant cells. BFA could potentiate UCN-01 and staurosporine-induced DNA fragmentation in HL60 cells. Cyclin B1/Cdc2 kinase activity decreased after BFA treatment in HL60 cells, indicating that BFA-induced DNA fragmentation was independent of a cyclin B1/Cdc2 kinase upregulation pathway. Cycloheximide could not prevent BFA-induced DNA fragmentation in HL60 cells, suggesting that protein synthesis is not needed for HL60 cells to undergo apoptosis. On the contrary, cycloheximide blocked BFA-induced DNA fragmentation in HT-29 cells, indicating that apoptosis in HT-29 cells requires macromolecular synthesis. Cell-free system experiments suggested that cytosolic proteins play an important role in triggering DNA fragmentation during apoptosis induced by BFA. Our results show that transduction signaling pathways play central roles in apoptotic regulation.
Shao
R G
RG
DNA Topology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Shimizu
T
T
Pommier
Y
Y
D000470:Alkaloids / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D020126:Brefeldin A; D002166:Camptothecin / Q000494:pharmacology; D002474:Cell-Free System; D019926:Cyclin B; D056744:Cyclin B1; D016213:Cyclins / Q000037:antagonists & inhibitors / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D003517:Cyclopentanes / Q000494:pharmacology*; D053938:DNA Fragmentation / Q000187:drug effects; D004273:DNA, Neoplasm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D018922:HL-60 Cells / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D019073:HT29 Cells / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D006801:Humans; D009154:Mutation / Q000502:physiology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D019311:Staurosporine / Q000494:pharmacology / Q000031:analogs & derivatives; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1; D016213:Cyclins; D003517:Cyclopentanes; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D011500:Protein Synthesis Inhibitors; D016159:Tumor Suppressor Protein p53; D020126:Brefeldin A; D005047:Etoposide; C054852:7-hydroxystaurosporine; D003513:Cycloheximide; D019311:Staurosporine; D002166:Camptothecin